Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Amphivena Therapeutics Inc is a privately held immuno-oncology company based in SSF, that is developing selective T cell engagers for treatment of hematological and solid tumors. AMV564, our lead molecule, has demonstrated novel clinical activity in rapidly and selectively eliminating leukemic blasts in AML and granulocytic/monocytic MDSCs while sparing normal myeloid cells, providing a unique opportunity to explore the impa...
Amphivena Therapeutics Inc is a privately held immuno-oncology company based in SSF, that is developing selective T cell engagers for treatment of hematological and solid tumors. AMV564, our lead molecule, has demonstrated novel clinical activity in rapidly and selectively eliminating leukemic blasts in AML and granulocytic/monocytic MDSCs while sparing normal myeloid cells, providing a unique opportunity to explore the impact of depleting MDSCs in cancers.

List your booth number for exhibitions, ask us